Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. Biochemical Reagents
  4. Peptides
  5. NB805466

Novus Biologicals™ MAP3K8/Tpl2/COT Antibody Blocking Peptide
SDP

Catalog No. NB805466
Change view
Click to view available options
Quantity:
0.25 mg
1 product options available for selection
Product selection table with 1 available options. Use arrow keys to navigate and Enter or Space to select.
Catalog No. Quantity
NB805466 0.25 mg
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 1 options available.
1 options
Catalog No. NB805466 Supplier Novus Biologicals™ Supplier No. NBP162178PEP

Customers require a valid business account associated to their profile to access pricing and ordering options.

missing translation for 'validMainframeMsg'

Specifications

Gene ID (Entrez) 1326
Species Human
Purity >85%, by HPLC
Concentration 2.5 mg/mL
Content And Storage Store at -20°C. Avoid freeze/thaw cycles.
For Use With (Application) This Peptide is Useful as a Blocking Peptide for NBP1-62178
Gene Alias Cancer Osaka thyroid oncogene, c-COT, cot (cancer Osaka thyroid) oncogene, COTMEKK8, EC 2.7.11.25, ESTF, ESTFLJ10486, Ewing sarcoma transformant, mitogen-activated protein kinase kinase kinase 8, Proto-oncogene c-Cot, proto-oncogene serine/threoine protein kinase, Serine/threonine-protein kinase cot, Tpl-2, TPL2, Tumor progression locus 2, tumor progression locus-2
Gene Symbol MAP3K8
Quantity 0.25 mg
Research Category Angiogenesis, Cancer, Protein Kinase
Storage Buffer Sodium Bicarbonate buffer, pH 8.00 containing up to 10% DMSO
Show More Show Less
Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.